title: Drug-induced acute kidney injury in neonates.
abstract: OBJECTIVE
  Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality in critically ill neonates. Nephrotoxic medication exposure is common in neonates. Nephrotoxicity represents the most potentially avoidable cause of AKI in this population.
  
  
  RESULTS
  Recent studies in critically ill children revealed the importance of recognizing AKI and potentially modifiable risk factors for the development of AKI such as nephrotoxic medication exposures. Data from critically ill children who have AKI suggest that survivors are at risk for the development of chronic kidney disease. Premature infants are born with incomplete nephrogenesis and are at risk for chronic kidney disease. The use of nephrotoxic medications in the neonatal intensive care unit is very common; yet the effects of medication nephrotoxicity on the short and long-term outcomes remains highly understudied.
  
  
  CONCLUSIONS
  The neonatal kidney is predisposed to nephrotoxic AKI. Our ability to improve outcomes for this vulnerable group depends on a heightened awareness of this issue. It is important for clinicians to develop methods to minimize and prevent nephrotoxic AKI in neonates through a multidisciplinary approach aiming at earlier recognition and close monitoring of nephrotoxin-induced AKI.
authors.affiliation: aDivision of Neonatology, Department of Pediatrics, University of Kentucky, Lexington, Kentucky bDivision of Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama cDivision of Nephrology, Department of Pediatrics and Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.
authors.forename: Mina H
authors.initials: MH
authors.lastname: Hanna
authors.forename: David J
authors.initials: DJ
authors.lastname: Askenazi
authors.forename: David T
authors.initials: DT
authors.lastname: Selewski
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D000212:Acyclovir / Q000009:adverse effects; D000617:Aminoglycosides / Q000009:adverse effects; D000666:Amphotericin B / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D014640:Vancomycin / Q000009:adverse effects
chemical_list: D000617:Aminoglycosides; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014640:Vancomycin; D000666:Amphotericin B; D000212:Acyclovir